Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Guggenheim Capital LLC

Guggenheim Capital LLC decreased its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 16.2% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,783 shares of the biopharmaceutical company’s stock after selling 2,465 shares during the quarter. Guggenheim Capital LLC’s holdings in Alnylam Pharmaceuticals were worth $3,008,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Regeneron Pharmaceuticals Inc. acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter worth about $1,045,822,000. Norges Bank purchased a new stake in Alnylam Pharmaceuticals in the fourth quarter valued at approximately $577,941,000. Raymond James Financial Inc. acquired a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $65,295,000. Jennison Associates LLC purchased a new position in Alnylam Pharmaceuticals during the fourth quarter worth approximately $61,160,000. Finally, Proficio Capital Partners LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 25,929.6% in the 4th quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock valued at $45,570,000 after purchasing an additional 192,916 shares during the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Stock Up 1.8 %

ALNY stock opened at $234.56 on Friday. The company has a market capitalization of $30.51 billion, a P/E ratio of -108.09 and a beta of 0.30. The firm has a 50 day simple moving average of $249.14 and a 200-day simple moving average of $256.97. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the stock from $280.00 to $328.00 in a report on Monday, March 24th. Stifel Nicolaus raised their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a report on Monday, March 31st. Canaccord Genuity Group boosted their target price on Alnylam Pharmaceuticals from $385.00 to $390.00 and gave the stock a “buy” rating in a report on Friday, March 21st. Scotiabank increased their target price on shares of Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the stock a “sector outperform” rating in a research report on Monday, March 31st. Finally, Morgan Stanley reduced their price target on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an “equal weight” rating on the stock in a research report on Friday, April 11th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $315.58.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 663 shares of the business’s stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.21, for a total transaction of $169,204.23. Following the completion of the sale, the executive vice president now owns 14,321 shares in the company, valued at $3,654,862.41. The trade was a 4.42 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction dated Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Insiders have sold 71,234 shares of company stock worth $19,958,097 over the last quarter. 1.50% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.